Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.49 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7902186 | 1.00 | FOLH1 (0.58) | FOLH1LMNACCKBRHDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL7903946 | 0.99 | FOLH1 (0.57) | FOLH1LMNACCKBRHDAC1HDAC2 | |
| SCHEMBL8726206 | 0.90 | KMT2A (0.51) | FOLH1LMNACCKBRHDAC1HDAC2 | |
| SCHEMBL4464533 | 0.85 | FOLH1 (0.49) | FOLH1LMNACCKBRNAALAD2GMNN | |
| SCHEMBL14497677 | 0.85 | FOLH1 (0.49) | FOLH1LMNACCKBRNAALAD2GMNN | |
| SCHEMBL7902095 | 0.84 | FOLH1 (0.46) | FOLH1LMNANAALAD2RIMKLAKMT2A | |
| SCHEMBL7894806 | 0.84 | FOLH1 (0.49) | FOLH1LMNACCKBRGAANAALAD2 | |
| SCHEMBL7906574 | 0.84 | FOLH1 (0.49) | FOLH1LMNACCKBRGAANAALAD2 | |
| SCHEMBL7902098 | 0.84 | FOLH1 (0.46) | FOLH1LMNANAALAD2RIMKLAKMT2A | |
| SCHEMBL9014687 | 0.84 | CA2 (0.56) | FOLH1LMNAGMNNALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0651740-B1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LTD (GB) | 1998-10-21 | — | — | EP | claimed |
| US-5714148-A | PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | claimed |
| EP-0651740-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1995-05-10 | — | — | EP | claimed |
| US-5405990-A | For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents | ZENECA LIMITED (GB) | 1995-04-11 | — | — | US | claimed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | claimed |
| US-20200216818-A1 | VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2020-07-09 | — | — | US | disclosed |
| EP-3010518-B1 | VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2020-06-10 | — | — | EP | disclosed |
| US-20160130564-A1 | VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2016-05-12 | — | — | US | disclosed |
| EP-3010518-A1 | VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202977-A1 | VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2014-12-24 | — | — | WO | disclosed |
| EP-0919622-B1 | Surface expression of enzyme in gene directed prodrug therapy | CANCER RES CAMPAIGN TECH (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20040014187-A1 | Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-01-22 | — | — | US | disclosed |
| EP-0774005-A1 | SURFACE EXPRESSION OF ENZYME IN GENE DIRECTED PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| EP-0772455-A2 | INTRACELLULAR EXPRESSION OF CARBOXYPEPTIDASE G2 IN ENZYME PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-05-14 | — | — | EP | disclosed |
| US-5587161-A | TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME | ZENECA LIMITED (GB) | 1996-12-24 | — | — | US | disclosed |
| WO-1996003515-A2 | SURFACE EXPRESSION OF ENZYME IN GENE DIRECTED PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
| WO-1996003151-A2 | INTRACELLULAR EXPRESSION OF CARBOXYPEPTIDASE G2 IN ENZYME PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
| EP-0651740-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| US-5405990-A | For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents | ZENECA LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |